Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials

Circulation

Volumn 135, Issue 8, 2017, Pages 720-723

  Belalcazar, L Maria ^a   Ballantyne, Christie M ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cardiovascular diseases; diabetes mellitus; diet; exercise; obesity; prevention and control

Indexed keywords

EMPAGLIFLOZIN; LIRAGLUTIDE; SEMAGLUTIDE; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC PATIENT; DIET; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; WEIGHT REDUCTION; BODY WEIGHT LOSS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DIABETIC COMPLICATION; FEMALE; HEART INFARCTION; LIFESTYLE; MALE; MIDDLE AGED; MORTALITY;

CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; WEIGHT LOSS;

EID: 85013427952     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024627     Document Type: Review

References (5)

1. Look AHEAD Research Group Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013 369 145 154
2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720.
3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 375 311 322. doi: 10.1056/NEJMoa1603827.
4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN-6 Investigators Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 375 1834 1844
5. Look AHEAD Research Group Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016 4 913-921